Fatigue News and Research

RSS

CHOP's patient safety team recognized for work alarm fatigue in hospital units

A patient safety team at The Children's Hospital of Philadelphia who analyzed the problem of alarm fatigue in hospital units has been recognized for the best research paper of 2014 in a journal dedicated to biomedical technology.

8 May 2015

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare today announced the start of a Phase III clinical trial programme to evaluate the safety and efficacy of dolutegravir (Tivicay) and rilpivirine (Edurant) as maintenance therapy for adult patients with HIV.

6 May 2015

1 in 5 people to develop heart failure in developed countries

One person in five is expected to develop heart failure in developed countries, a disease with no cure but which is largely preventable.

6 May 2015

Protein Sciences, CTH@H to provide Flublok vaccine to home health and hospice agencies in Connecticut

Protein Sciences Corporation, along with The Connecticut Association for Healthcare at Home, announced a new partnership today that will bring Flublok influenza vaccine to home health and hospice agencies across the state. As a new affinity partner of CTH@H, Protein Sciences will make Flublok available to CTH@H member agencies for the 2015/16 flu season.

5 May 2015

Applying palliative care principles to transform geriatric emergency care may reduce hospital admissions

Applying palliative care principles to emergency departments may reduce the number of geriatric patients admitted to intensive care units, possibly extending lives and reducing Medicare costs, according to a three-year analysis by Mount Sinai researchers set to be published in the May edition of Health Affairs, which can be found online.

5 May 2015

Moderate exercise on a regular basis may improve cancer treatments

Kansas State University kinesiology research offers encouraging information for cancer patients: A brisk walk or a slow jog on a regular basis may be the key to improved cancer treatments.

5 May 2015

Researchers reveal potential mode of drug resistance in malaria parasites

Scientists have uncovered a potential mode of parasite drug resistance in malaria infection, according to a report published in The Journal of Experimental Medicine.

5 May 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014.

30 Apr 2015

Adult survivors of preterm births at higher risk of developing COPD

Adult survivors of preterm births may have a lung capacity that resembles the healthy elderly or casual smokers by the time they reach their early 20s, according to a University of Oregon study.

30 Apr 2015

Night shift workers classified as alert insomniacs have highest level of impairment in work productivity

A new study of night shift workers suggests that overnight occupational and cognitive impairment is more strongly correlated to insomnia than it is to sleepiness.

28 Apr 2015

Neuronetics completes Series F Financing Round

Neuronetics, Inc., the established market leader in transcranial magnetic stimulation (TMS) technology, announced today the completion of its Series F Financing Round, which included investment from GE Ventures, as well as its original investor base totaling $34.3 million.

27 Apr 2015

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.

From Baxter International Inc. 27 Apr 2015

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Phase 3 results presented today at The International Liver Congress 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence.

27 Apr 2015

Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

Results presented today at The International Liver Congress 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.

25 Apr 2015

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).

25 Apr 2015

Research highlights value of serological testing for Coeliac disease in anyone with symptoms

Coeliac disease is one of the most common life-long conditions in Europe, yet many people remain undiagnosed and lengthy diagnostic delays may be putting lives at risk. Today, doctors are being urged to consider testing for Coeliac disease in anyone showing signs and symptoms of the condition and to consider screening everyone in high-risk groups.

25 Apr 2015

Loyola study reports significant increase in major depression during recent Great Recession

The recent Great Recession was accompanied by a significant and sustained increase in major depression in U.S. adults, according to a Loyola study published in the Journal of Clinical Psychiatry.

25 Apr 2015

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

25 Apr 2015

Lucideon Receives ISO 17025 Accreditation for Wear Testing

Lucideon, the international materials technology company, has been awarded ISO/IEC 17025:2005 accreditation for the total wear testing of hip joints...

From Lucideon 24 Apr 2015

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Results presented today at The International Liver Congress 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high sustained virologic response rates 12 weeks post treatment (SVR12) in patients with chronic hepatitis C virus (HCV) infection who have decompensated liver disease (cirrhosis) or have undergone liver transplantation.

23 Apr 2015

Fatigue News and Research

CHOP's patient safety team recognized for work alarm fatigue in hospital units

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

1 in 5 people to develop heart failure in developed countries

Protein Sciences, CTH@H to provide Flublok vaccine to home health and hospice agencies in Connecticut

Applying palliative care principles to transform geriatric emergency care may reduce hospital admissions

Moderate exercise on a regular basis may improve cancer treatments

Researchers reveal potential mode of drug resistance in malaria parasites

Neurocrine reports net loss of $1.2 million for first quarter 2015

Adult survivors of preterm births at higher risk of developing COPD

Night shift workers classified as alert insomniacs have highest level of impairment in work productivity

Neuronetics completes Series F Financing Round

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

Research highlights value of serological testing for Coeliac disease in anyone with symptoms

Loyola study reports significant increase in major depression during recent Great Recession

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lucideon Receives ISO 17025 Accreditation for Wear Testing

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News